BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 2021;9:1075. [PMID: 34572263 DOI: 10.3390/biomedicines9091075] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Jiang X, Zhao Z. Inhibition or promotion, the potential role of arginine metabolism in immunotherapy for colorectal cancer. All Life 2023;16. [DOI: 10.1080/26895293.2022.2163306] [Reference Citation Analysis]
2 Mohd Salim NH, Mussa A, Ahmed N, Ahmad S, Yean Yean C, Hassan R, Uskoković V, Mohamud R, Che Jalil NA. The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. Biomedicines 2023;11. [PMID: 36672682 DOI: 10.3390/biomedicines11010173] [Reference Citation Analysis]
3 Merhi M, Ahmad F, Taib N, Inchakalody V, Uddin S, Shablak A, Dermime S. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. Semin Cancer Biol 2023;89:1-17. [PMID: 36621515 DOI: 10.1016/j.semcancer.2023.01.001] [Reference Citation Analysis]
4 Vatankhah F, Salimi N, Khalaji A, Baradaran B. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches. Int Immunopharmacol 2023;114:109526. [PMID: 36481527 DOI: 10.1016/j.intimp.2022.109526] [Reference Citation Analysis]
5 Maugeais M, Péron J, Dalle S, Boespflug A, Duruissaux M, Corbaux P, Reverdy T, Sahin G, Rabier A, Lopez J, Freymond N, Maillet D. Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines 2022;11. [PMID: 36672591 DOI: 10.3390/biomedicines11010083] [Reference Citation Analysis]
6 Jung M, Lee JA, Yoo SY, Bae JM, Kang GH, Kim JH. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas. Mod Pathol 2022;35:2011-22. [PMID: 35869301 DOI: 10.1038/s41379-022-01137-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Xia C, Cai Y, Ren S, Xia C. Role of microbes in colorectal cancer therapy: Cross-talk between the microbiome and tumor microenvironment. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1051330] [Reference Citation Analysis]
8 Sové RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J Immunother Cancer 2022;10. [PMID: 36323435 DOI: 10.1136/jitc-2022-005414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Niu M, Chen C, Li W, Ma J, Zhang X, Zhang C, Jiang X, Zhao Z, Li Z. Development and validation of immune-related genomics nomogram for prognostic prediction in left- and right-side colorectal cancer.. [DOI: 10.21203/rs.3.rs-2203965/v1] [Reference Citation Analysis]
10 Deng H, Zhang J, Zheng Y, Li J, Xiao Q, Wei F, Han W, Xu X, Zhang Y. CCDC25 may be a potential diagnostic and prognostic marker of hepatocellular carcinoma: Results from microarray analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.878648] [Reference Citation Analysis]
11 Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, Katuch V. Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer. World J Gastroenterol 2022; 28(33): 4744-4761 [DOI: 10.3748/wjg.v28.i33.4744] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xie Y, Yan F, Wang X, Yu L, Yan H, Pu Q, Li W, Yang Z. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma. Cancer Med 2022. [PMID: 36043445 DOI: 10.1002/cam4.5064] [Reference Citation Analysis]
13 Wang C, Tang Y, Ma H, Wei S, Hu X, Zhao L, Wang G. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. Front Genet 2022;13:919389. [DOI: 10.3389/fgene.2022.919389] [Reference Citation Analysis]
14 Zhang S, Wang Y, Zhang P, Ai L, Liu T. Cardiovascular Outcomes in the Patients With Colorectal Cancer: A Multi-Registry-Based Cohort Study of 197,699 Cases in the Real World. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.851833] [Reference Citation Analysis]
15 Zhang W, Zhang J, Liu T, Xing J, Zhang H, Wang D, Tang D. Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention. J Cancer Res Clin Oncol 2022. [PMID: 35661254 DOI: 10.1007/s00432-022-04081-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhang M, Fang Z, Cui M, Liu K. Multifunctional Metal Complex-based Gene Delivery for tumor immune checkpoint blockade combination therapy. J Drug Target 2022;:1-34. [PMID: 35311603 DOI: 10.1080/1061186X.2022.2056186] [Reference Citation Analysis]
17 Ragone A, Salzillo A, Spina A, Naviglio S, Sapio L. Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines. Front Pharmacol 2022;13:837503. [PMID: 35273510 DOI: 10.3389/fphar.2022.837503] [Reference Citation Analysis]
18 Ghorbaninezhad F, Asadzadeh Z, Masoumi J, Mokhtarzadeh A, Kazemi T, Aghebati-Maleki L, Shotorbani SS, Shadbad MA, Baghbanzadeh A, Hemmat N, Bakhshivand M, Baradaran B. Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside. Life Sci 2022;:120466. [PMID: 35271882 DOI: 10.1016/j.lfs.2022.120466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
19 Naccache R, Belkouchi Y, Lawrance L, Benatsou B, Hadchiti J, Cournede P, Ammari S, Talbot H, Lassau N. Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker. Cancers 2022;14:1337. [DOI: 10.3390/cancers14051337] [Reference Citation Analysis]
20 Zhang J, Wu K, Shi C, Li G. Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light. Curr Treat Options Oncol 2022;23:1777-92. [PMID: 36279081 DOI: 10.1007/s11864-022-01027-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zheng Z, Bian C, Wang H, Su J, Meng L, Xin Y, Jiang X. Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer. Ther Adv Med Oncol 2022;14:175883592211383. [DOI: 10.1177/17588359221138383] [Reference Citation Analysis]
22 Baghbani E, Noorolyai S, Rahmani S, Shanehbandi D, Shadbad MA, Aghebati-Maleki L, Mokhtarzadeh A, Brunetti O, Fasano R, Silvestris N, Baradaran B. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. Biomed Pharmacother 2022;145:112370. [PMID: 34862113 DOI: 10.1016/j.biopha.2021.112370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]